All Stories

  1. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

    Article • Expert Opinion on Pharmacotherapy, January 2019, Taylor & Francis

    Thibault MESPLEDE

  2. Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

    Article • Expert Opinion on Investigational Drugs, November 2018, Taylor & Francis

    Thibault MESPLEDE

  3. Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”

    Article • mBio, September 2018, ASM Journals

    Thibault MESPLEDE

  4. Reply to Darcis and Berkhout

    Article • The Journal of Infectious Diseases, August 2018, Oxford University Press (OUP)

    Thibault MESPLEDE

  5. Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

    Article • PLoS ONE, July 2018, PLOS

    Thibault MESPLEDE

  6. Where are we with injectables against HIV infection and what are the remaining challenges?

    Article • Expert Review of Anti-infective Therapy, January 2018, Taylor & Francis

    Thibault MESPLEDE

  7. Investigational HIV integrase inhibitors in phase I and phase II clinical trials

    Article • Expert Opinion on Investigational Drugs, September 2017, Taylor & Francis

    Thibault MESPLEDE, Dr Mark Wainberg

  8. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1

    Article • Antimicrobial Agents and Chemotherapy, September 2017, ASM Journals

    Thibault MESPLEDE

  9. HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity

    Article • Journal of Virology, August 2017, ASM Journals

    Thibault MESPLEDE

  10. HIV drug resistance against strand transfer integrase inhibitors

    Article • Retrovirology, June 2017, Springer Science + Business Media

    Thibault MESPLEDE

  11. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

    Article • Infection Genetics and Evolution, December 2016, Elsevier

    Thibault MESPLEDE

  12. The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir

    Article • AIDS, September 2016, Wolters Kluwer Health

    Thibault MESPLEDE

  13. Will LEDGIN molecules be able to play a role in a cure for HIV infection?

    Article • EBioMedicine, June 2016, Elsevier

    Thibault MESPLEDE

  14. Might dolutegravir be part of a functional cure for HIV?1

    Article • Canadian Journal of Microbiology, May 2016, Canadian Science Publishing

    Dr Mark Wainberg, Thibault MESPLEDE

  15. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

    Article • Retrovirology, April 2016, Springer Science + Business Media

    Thibault MESPLEDE

  16. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

    Article • Journal of Antimicrobial Chemotherapy, April 2016, Oxford University Press (OUP)

    Thibault MESPLEDE

  17. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

    Article • Journal of Antimicrobial Chemotherapy, March 2016, Oxford University Press (OUP)

    Thibault MESPLEDE

  18. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir

    Article • AIDS, November 2015, Wolters Kluwer Health

    Thibault MESPLEDE

  19. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239

    Article • Journal of Virology, September 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  20. HIV-1 Group O Resistance Against Integrase Inhibitors

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, September 2015, Wolters Kluwer Health

    Thibault MESPLEDE

  21. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance

    Article • Journal of Virology, August 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  22. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

    Article • Journal of Virology, August 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  23. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

    Article • Viruses, July 2015, MDPI AG

    Thibault MESPLEDE

  24. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout

    Article • Journal of Antimicrobial Chemotherapy, July 2015, Oxford University Press (OUP)

    Thibault MESPLEDE

  25. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B

    Article • AIDS, July 2015, Wolters Kluwer Health

    Thibault MESPLEDE

  26. A resveratrol analog termed 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor

    Article • Journal of Medical Virology, June 2015, Wiley

    Thibault MESPLEDE

  27. Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

    Article • PLoS ONE, June 2015, PLOS

    Thibault MESPLEDE

  28. Dolutegravir inhibits HIV-1 Env evolution in primary human cells

    Article • AIDS, March 2015, Wolters Kluwer Health

    Thibault MESPLEDE

  29. Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity

    Article • Antimicrobial Agents and Chemotherapy, February 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  30. Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

    Article • Journal of Virology, February 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  31. Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

    Article • Antiviral Chemistry and Chemotherapy, February 2015, SAGE Publications

    Thibault MESPLEDE

  32. Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors

    Article • Antimicrobial Agents and Chemotherapy, January 2015, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  33. Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

    Article • Journal of Virology, December 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  34. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline

    Article • Journal of Antimicrobial Chemotherapy, November 2014, Oxford University Press (OUP)

    Thibault MESPLEDE

  35. The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir

    Article • Antimicrobial Agents and Chemotherapy, October 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  36. Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency

    Article • Viruses, September 2014, MDPI AG

    Thibault MESPLEDE

  37. HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase

    Article • Antimicrobial Agents and Chemotherapy, September 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  38. Exposure to Entry Inhibitors Alters HIV Infectiousness and Sensitivity to Broadly Neutralizing Monoclonal Antibodies

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, September 2014, Wolters Kluwer Health

    Thibault MESPLEDE

  39. Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

    Article • Viruses, August 2014, MDPI AG

    Thibault MESPLEDE

  40. Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors

    Article • Journal of Virology, June 2014, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  41. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity

    Article • Journal of Antimicrobial Chemotherapy, June 2014, Oxford University Press (OUP)

    Thibault MESPLEDE

  42. Integrase strand transfer inhibitors in the management of HIV-positive individuals

    Article • Annals of Medicine, March 2014, Taylor & Francis

    Thibault MESPLEDE

  43. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

    Article • AIDS, March 2014, Wolters Kluwer Health

    Thibault MESPLEDE

  44. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

    Article • Retrovirology, January 2014, Springer Science + Business Media

    Thibault MESPLEDE

  45. What if HIV were unable to develop resistance against a new therapeutic agent?

    Article • BMC Medicine, November 2013, Springer Science + Business Media

    Thibault MESPLEDE

  46. Integrase Strand Transfer Inhibitors in HIV Therapy

    Article • Infectious Diseases and Therapy, November 2013, Springer Science + Business Media

    Thibault MESPLEDE

  47. Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

    Article • Antimicrobial Agents and Chemotherapy, September 2013, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  48. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors

    Article • Antiviral Research, June 2013, Elsevier

    Thibault MESPLEDE

  49. Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-Dependent Endocytosis

    Article • Journal of Virology, May 2013, ASM Journals

    Dr Mark Wainberg, Thibault MESPLEDE

  50. Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity

    Article • Retrovirology, January 2013, Springer Science + Business Media

    Thibault MESPLEDE

  51. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

    Article • Retrovirology, January 2013, Springer Science + Business Media

    Thibault MESPLEDE

  52. Evolution of HIV integrase resistance mutations

    Article • Current Opinion in Infectious Diseases, December 2012, Wolters Kluwer Health

    Thibault MESPLEDE

  53. HIV Drug Resistance and the Advent of Integrase Inhibitors

    Article • Current Infectious Disease Reports, November 2012, Springer Science + Business Media

    Thibault MESPLEDE

  54. The development of novel HIV integrase inhibitors and the problem of drug resistance

    Article • Current Opinion in Virology, October 2012, Elsevier

    Thibault MESPLEDE

  55. A high-throughput assay for HIV-1 integrase 3′-processing activity using time-resolved fluorescence

    Article • Journal of Virological Methods, September 2012, Elsevier

    Thibault MESPLEDE

  56. Resistance to HIV integrase inhibitors

    Article • Current Opinion in HIV and AIDS, September 2012, Wolters Kluwer Health

    Thibault MESPLEDE

  57. HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug

    Article • Antimicrobial Agents and Chemotherapy, May 2012, ASM Journals

    Thibault MESPLEDE

  58. Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

    Article • Journal of Virology, December 2011, ASM Journals

    Thibault MESPLEDE